Description

This acquisition will allow BARDA to invest Project BioShield funds for the advanced development, US Food and Drug Administration (FDA) licensure, procurement, shipping, and vendor managed inventory (VMI) storage of MARV monovalent vaccine. This contract was awarded on a hybrid cost reiumbursement/fixed price basis as circumstances do not allow the agency to define its requirements sufficiently to allow for a fixed-price type contract.

Award Details

Classification

Place of Performance

Contracting Office

Contacts